Bid Banana
PricingBid helpAPILog inStart free trial
Log inStart free trial

Learn more

  • Florida guideFlorida Bids and Bidding Guide
  • Healthcare RFPsHealthcare and Medical Services Bids and Bidding Guide
More healthcare and medical services bids →Must-win bid? Bring in The Bid Lab →
Bid Banana
SearchPricingBid helpBrowse bidsAPISupportFAQPrivacy PolicyTerms of UseAI Use Policy

This website and its content is copyright of The Bid Lab © 2026. The Bid Lab is a trademark of Bid Lab, LLC. All rights reserved.

  1. Bid Banana
  2. ›Closed bids
  3. ›Florida
  4. ›Healthcare and Medical Services
  5. ›bioLytical INSTI HIV – 1/HIV-2 Antibody Test

Florida Department of Health (DOH)·Florida

bioLytical INSTI HIV – 1/HIV-2 Antibody Test

Closes 4/23/2026$2.5M – $3.5MSole Source
Bid source

This opportunity has closed.

Bid Banana tracks 1.6M+ bids and awards across all 50 states. Save a search and we'll email your new matches, daily or weekly — so the next one reaches you with time to bid.

Get alerted next time

Description

The Florida Department of Health's Bureau of Communicable Disease, HIV/AIDS Section is seeking to purchase FDA-approved, INSTI HIV – 1/HIV-2 Antibody Test devices from bioLytical. The test provides results in 60 seconds and is intended for at-risk communities and testing kit training. The department is requesting authorization to purchase the devices as a single source due to their uniqueness and necessity. • The test is a 3rd generation HIV rapid point of care test. • The test provides results in 60 seconds. • The test is intended for at-risk communities and testing kit training. • The department is seeking to purchase the devices for a 3-year term. • The estimated dollar amount for the purchase is $3,000,000.00.

Attached files

Contact

Keshauna Johnson(Purchasing Contact)

[email protected]

(850) 558-9723

Key dates

Opened
4/2/2026
Closes
4/23/2026
Duration
3 years

Last updated

Details

Type
Sole Source
Industry
Healthcare and Medical Services
NAICS
621511
Solicitation №
EXP2666

Budget estimate

$2,500,000 – $3,500,000

The estimated budget for this opportunity is $3,000,000.00, as stated in the document. This amount is likely to be the total value of the contract over the 3-year term. The actual budget may vary depending on the terms of the contract and the performance of the vendor.

AI estimate from the solicitation

Similar opportunities

Matched by Bid Banana AI™

Bid Banana · 1.6M+ bids and awards 🍌

You found this one too late. Don't find the next one too late.

Bid Banana searches open government bids across all 50 states, updated daily. Save a search once and we email you your new matches, daily or weekly, while there is still time to win them.

1.6M+
bids & awards
All 50
states
4,000+
agencies
Start your 7-day free trial

Plans from $49.99/month. Cancel anytime, no setup fees.

Built by The Bid Lab, answering RFPs since 2017.

Department of Public Health·South Carolina

Top match · 72%

Sole Source Procurement for INSTI HIV‑1/HIV‑2 Antibody Test Kits and Controls

Rolling / TBD closeOpened 9/8/2026

U.S. National Institutes of Health·United States of America

64% match

HIV/AIDS Clinical Trials Network Laboratory Centers

Closes 1/21/2027Opened 4/8/2026

U.S. Centers for Disease Control - NCHHSTP·United States of America

64% match

Direct-to-Consumer Distribution of HIV and other STI Self-Tests

Closes 9/29/2027Opened 7/27/2026

U.S. National Institutes of Health·United States of America

62% match

Integrated Specific Pathogen Free Research Models and Human New Approach Methodologies to Advance HIV/AIDS Research (U42 Clinical Trial Not Allowed)

Closes 1/24/2027Opened 5/20/2026

U.S. National Institutes of Health·United States of America

62% match

Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances (R34 Clinical Trial Required)

Closes 3/16/2027Opened 1/8/2025

U.S. National Institutes of Health·United States of America

62% match

Centers for Structural Biology of HIV and Other Infectious Diseases (U54 Clinical Trial Not Allowed)

Closes 5/28/2027Opened 12/22/2025

U.S. National Institutes of Health·United States of America

62% match

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

Closes 2/7/2027Opened 12/8/2025

U.S. National Institutes of Health·United States of America

61% match

Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed)

Closes 11/16/2027Opened 1/8/2025

U.S. National Institutes of Health·United States of America

61% match

Improved Drug Susceptibility Testing (DST) for Mycobacteria

Closes 5/27/2027Opened 6/24/2026

U.S. Food and Drug Administration·United States of America

61% match

Synthesis and Biological Activity Assessment of Different Diastereomers in siRNA Drug LEQVIO (Inclisiran) (U01) Clinical Trial Not Allowed

Rolling / TBD closeOpened 11/24/2023

U.S. National Institutes of Health·United States of America

61% match

Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Phase 2

Closes 6/7/2027Opened 8/20/2026

U.S. National Institutes of Health·United States of America

61% match

Immune Tolerance Network (UM1 Clinical Trial Required)

Closes 1/29/2027Opened 6/24/2026

U.S. National Institutes of Health·United States of America

61% match

HIV/AIDS Clinical Trials Network Clinical Trials Units

Closes 1/21/2027Opened 4/8/2026

U.S. Department Of Veterans Affairs·Florida

61% match

6632--FY27 Microbial Incubation ID and Susceptibility CPT

Closes 11/10/2026Opened 10/27/2026

U.S. Department Of Veterans Affairs·New York

61% match

6640--LAB - Immunochemistry (IHC) STAIN system CPT

Closes 10/31/2026Opened 7/22/2026

U.S. National Institutes of Health·United States of America

61% match

Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)

Closes 11/5/2027Opened 1/8/2025

U.S. Department Of Health And Human Services·United States of America

61% match

Pre-Clinical Models of Infectious Diseases

Closes 12/7/2026Opened 10/19/2026

U.S. National Institutes of Health·United States of America

61% match

High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)

Closes 3/6/2027Opened 8/2/2024

Iowa State University·Iowa

61% match

Blood Spot and Dried Urine Testing

Closes 11/6/2026Opened 10/23/2026

U.S. National Institutes of Health·United States of America

60% match

Mechanistic Evaluation of Therapeutic Targets derived from Treatable Traits to Improve CNS Outcomes in People with HIV (R21/R33 Clinical Trial Not Allowed)

Closes 10/28/2027Opened 6/9/2025

U.S. National Institutes of Health·United States of America

60% match

Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional)

Closes 6/20/2029Opened 11/18/2025

U.S. Department Of Transportation·United States of America

60% match

Experimental and Mathematical Biomechanics Injury Research IDIQ

Closes 11/30/2026Opened 10/15/2026

U.S. National Institutes of Health·United States of America

60% match

Partnerships for Advancing Development of Diagnostics for Infectious Diseases

Closes 10/13/2027Opened 9/24/2026

U.S. National Institutes of Health·United States of America

60% match

NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)

Closes 5/25/2029Opened 6/16/2025

U.S. National Institutes of Health·United States of America

60% match

Implementation and Evaluation of Databases to Examine AIDS

Closes 5/26/2027Opened 5/27/2025